Evervie Health Limited signed a Letter of Intent with Elekta Solutions AB, Sweden, on October 20, 2026, for the proposed procurement of ten HARMONY linear accelerator (LINAC) systems. The deal value is expected to range between $11 million and $15 million, with payment terms set in Swedish krona (SEK).

The procurement is intended for operation by the company’s subsidiary, Optimus Oncology Private Limited. The Letter of Intent records the commercial intention to proceed but does not constitute a definitive sale and purchase agreement. Execution of the final Purchase and License Agreement remains subject to necessary approvals, financing arrangements, and applicable contractual conditions.

Procurement details and timeline

The LOI covers the supply of equipment, accessories, software, documentation, installation, and commissioning as per Elekta’s final offer. The delivery schedule is phased, with the first five units followed by the remaining five. Tentative completion of the phased delivery is projected by October 2028.

Corporate rebranding and website launch

Concurrent with the LOI announcement, the company launched its new official website at everviehealth.com. This change aligns with the corporate name transition from PVP Ventures Limited to Evervie Health Limited. The previous website, pvpglobal.com, has been replaced effective October 20, 2026.

What the numbers show

The disclosure highlights a strategic pivot toward healthcare infrastructure through a wholly owned subsidiary, Optimus Oncology Private Limited. While the headline value is quoted in USD ($11-15 million), the contractual payment obligation is denominated in SEK. This currency mismatch introduces foreign exchange exposure that will be managed through the final Purchase and License Agreement. Furthermore, the phased delivery over two years (through October 2028) suggests a gradual capital expenditure outflow rather than an immediate lump-sum investment, allowing for staggered financing arrangements.

Evervie Health Limited paid ₹13.46 crore in interest on its Non-Convertible Debentures (NCDs) on October 8, 2026. The payment covers interest due for the scheduled dates of December 31, 2026, and March 31, 2027.

The company, formerly known as PVP Ventures Limited, made the payment under Regulation 57 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This advance settlement applies to both Series A and Series B debentures, with no change to the quarterly interest payment frequency.

Interest payment breakdown

The total interest amount was split between two series of debentures. Series A accounted for a larger portion of the liability compared to Series B. The table below details the specific amounts payable for each scheduled date.

Note: Figures rounded to two decimal places for readability.

Key dates and details

The record date for both series was September 23, 2026. While the contractual due dates remained December 31, 2026, and March 31, 2027, the actual payment date was October 8, 2026. The last regular interest payment occurred on October 3, 2026. There were no delays or non-payment issues cited; the payment was explicitly made in advance.

What the numbers show

The advance payment clears the entire interest obligation for the next two quarters immediately after the previous quarter's payout. By settling the December 2026 and March 2027 dues in October 2026, the company eliminates near-term debt servicing liabilities for the remainder of FY26 and the first quarter of FY27. This action consolidates cash outflows into a single period rather than spreading them across three separate dates.